Savara, Inc. (SVRA)

Over the past six months, Savara, Inc.'s stock price has increased by 109.17%. Savara resubmitted its BLA for Molbreevi to the FDA in December 2025, requesting Priority Review, with a decision expected in February 2026 and potential approval by August 2026. In October 2025, Savara closed a public offering, raising approximately $149.5 million. Several analyst firms reiterated "Buy" ratings and raised price targets for SVRA following the BLA resubmission. In December 2025, Savara and PARI Pharma GmbH were granted a European patent for MOLBREEVI delivered via the eFlow Nebulizer System. Savara reported its Q3 2025 earnings in November 2025.

Information regarding demand seasonality for Savara, Inc.'s products is not explicitly available. Demand is primarily driven by clinical trial progress, regulatory approvals, and market launch, making traditional demand seasonality patterns unlikely to be significant at its current stage.

Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, operating within the Healthcare sector, specifically in Biotechnology and Pharmaceuticals. Their primary product candidate is molgramostim (MOLBREEVI), an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), administered once daily via the eFlow Nebulizer System.

Savara, Inc. is headquartered in Langhorne, Pennsylvania, United States. The company is pursuing a global approach for its lead product, with plans to submit Marketing Authorization Applications for Molbreevi to the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency in the first quarter of 2026.

Savara, Inc.'s brand reputation has been positive due to progress in clinical development and regulatory submissions. The successful BLA resubmission for Molbreevi and request for Priority Review have been viewed favorably. Molbreevi's efficacy data from the Phase 3 IMPALA-2 trial, published in the New England Journal of Medicine, has reinforced the drug's potential. The company has received a consensus "Buy" rating from analysts. The selection of PANTHERx Rare as the U.S. exclusive specialty pharmacy for MOLBREEVI enhances the company's commercial readiness.

Savara, Inc.'s ownership is a mix of institutional (72.71%), insider (12.31%), and public/individual investors (14.98%). Major institutional owners include NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, and BlackRock, Inc. James N. Topper owns the most shares among individual investors.